Background: Strict monitoring of the changes in biomarkers might aid clinicians to monitor the clinical course of the SARS-CoV-2 infection and intervene accordingly. The study was aimed to evaluate the laboratory parameters in severe and non-severe COVID-19 cases and its utility in predicting the duration of hospitalization. Methods: It was a retrospective study on seventy-nine COVID-19 patients. Data was collected for demographic details, clinical features and laboratory values for study analysis. Results: The mean (SD) of duration of hospital stay was 9.7 (4.5) days for severe patients and 8.3 (4.2) days for non-severe cases (p=0.08). The odds for death was 12.38 times (CI95%:1.36-112.41) in severe COVID-19 patients than the non-severe ones. Serum biomarkers like urea, liver enzymes were significantly higher in severe group whereas total protein, albumin, lymphocytes and eosinophils were significantly lower. The mean CRP-Albumin ratio (CAR) value was found to be 2.5 times higher in them (p<0.001). Duration of hospitalization was increased with rise in serum urea (by 47%), CAR (51%), eosinopenia (by 12%) and lymphopenia (by 12%). Conclusion: The findings suggested that close monitoring of these biomarkers can aid in improving recovery in patients of COVID-19.